Search tips
Search criteria

Results 1-3 (3)

Clipboard (0)
more »
Year of Publication
Document Types
1.  Safety Profile and Clinical Recommendations for the Use of Lapatinib 
Breast Care  2010;5(Suppl 1):16-21.
The toxicity profile of agents blocking the epidermal growth factor receptor pathway excludes many of the severe side effects commonly observed with cytotoxic chemotherapy. Like other tyrosine kinase inhibitors, lapatinib is generally well tolerated. Lapatinib exhibits specific toxicities, the most common being diarrhea and rash, which are mostly mild to moderate in severity. Cardiac toxicity is rarely seen with lapatinib. Generally, lapatinib-associated toxicities are manageable.
PMCID: PMC2931096  PMID: 20847928
Lapatinib; Tolerability; Rash; Diarrhea; Clinical management
2.  Adherence to Treatment Guidelines in Breast Cancer Care – a Retrospective Analysis of the ‘Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie’ 
Breast Care  2008;3(2):87-92.
The Organgruppe Mamma of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) performed a nationwide 3-phase analysis of the structure of care and standard of therapy given to patients with breast cancer from 2002 (4th quarter) to 2004 (4th quarter). The extent to which national and international treatment recommendations are implemented in routine clinical practice had so far not been evaluated in an interdisciplinary approach. No reliable data on the pattern of care of these patients have been published in Germany before.
Patients and Methods
The project included early breast cancer in the adjuvant and neoadjuvant setting as well as metastatic disease. We present the results of phase III of the AGO analysis, which are based on a survey conducted by the Organkommission Mamma in the 4th quarter of 2004.
Evaluation of the data reveals that treatment based on the guidelines is now being implemented very reliably in certain sectors. This is of particular relevance to the pattern of adjuvant treatment in early breast cancer. In contrast, in metastatic breast cancer (MBC), the complexity of the interdisciplinary treatment approach is complicating this kind of straightforward analysis.
The present analysis conducted by the AGO was the first attempt to analyse the treatment provided in patients presenting with MBC in a systematic fashion. The fundamental problem remains, irrespective of the stage of the tumour, that too few patients are treated in randomised clinical trials. The mission set by the AGO-Organkommission Mamma is the longitudinal observation of the therapy practices for breast cancer on the basis of the observations discussed here, which should ultimately benefit the optimisation of therapy quality in Germany.
PMCID: PMC2931081  PMID: 21373210
Breast cancer treatment; Healthcare research; Adjuvant treatment; Breast cancer, metastatic; Guideline adherence
3.  Practical Management Recommendations for Anti-ErbB2 Therapy with Lapatinib 
Breast Care  2008;3(Suppl 1):13-16.
PMCID: PMC2930991  PMID: 20824003

Results 1-3 (3)